Search This Blog

Monday, September 14, 2026

Veracyte acquires Convergent Genomics and UroAmp bladder cancer test platform

 

Veracyte acquires Convergent Genomics and UroAmp bladder cancer test platform for $150M upfront plus up to $30M milestones

  • Veracyte expects no change to its 2026 adjusted EBITDA guidance following the Convergent Genomics acquisition.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)